# Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer

> **NCT00607594** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 21 (actual)

## Conditions studied

- Adenocarcinoma of the Gastroesophageal Junction
- Adenocarcinoma of the Stomach
- Recurrent Gastric Cancer
- Stage III Gastric Cancer
- Stage III Esophageal Cancer
- Stage IV Esophageal Cancer
- Stage IV Gastric Cancer

## Interventions

- **DRUG:** saracatinib

## Key facts

- **NCT ID:** NCT00607594
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2010-03
- **Final completion:** 2012-04
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2018-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00607594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00607594, "Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer". Retrieved via MORVS 2026-11-02 from https://api.morvs.ai/clinical/NCT00607594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*